RPL7 — Ribosomal Protein L7
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">RPL7 — Ribosomal Protein L7</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>RPL7</td>
</tr>
<tr>
<td class="label">Name</td>
<td>Ribosomal Protein L7</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>8q12.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6130</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P18124</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000101290</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>L7, SAHM1</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>180436</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
RPL7 (Ribosomal Protein L7) encodes a component of the large 60S ribosomal subunit. While ribosomal proteins were historically viewed as structural components essential for protein synthesis, emerging research has revealed that RPL7 and other ribosomal proteins play crucial roles in various cellular processes beyond translation, including regulation of gene expression, cell cycle control, and neuronal function [1](https://pubmed.ncbi.nlm.nih.gov/12411577/). The involvement of ribosomal proteins in neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), has become an area of intense investigation [2](https://pubmed.ncbi.nlm.nih.gov/22911879/).
Function
Role in Protein Synthesis
RPL7 is a constituent of the 60S large ribosomal subunit, where it participates in the peptidyl transferase reaction and contributes to the structural integrity of the ribosome [3](https://pubmed.ncbi.nlm.nih.gov/9724655/). The protein contains an N-terminal acidic domain and a C-terminal basic DNA-binding domain, allowing it to interact with both RNA and DNA molecules [4](https://pubmed.ncbi.nlm.nih.gov/7926787/).
Beyond its canonical role in translation, RPL7 has been implicated in several extra-ribosomal functions:
Regulation of Gene Expression: RPL7 can function as a transcription factor, binding to specific DNA sequences and modulating gene expression [5](https://pubmed.ncbi.nlm.nih.gov/12411577/).
Cell Cycle Regulation: Studies have shown that RPL7 interacts with cell cycle regulators and can influence proliferation in certain cell types [6](https://pubmed.ncbi.nlm.nih.gov/18036208/).
Apoptosis Regulation: RPL7 has been reported to interact with p53 and other apoptosis-related proteins, suggesting a role in programmed cell death [7](https://pubmed.ncbi.nlm.nih.gov/15654334/).
Neuroprotective Functions: In neurons, RPL7 may contribute to cellular stress responses and protection against toxic insults [8](https://pubmed.ncbi.nlm.nih.gov/22911879/).Expression Pattern
RPL7 is ubiquitously expressed across all tissues, with high expression levels in metabolically active tissues including brain, liver, and kidney. Within the brain, RPL7 is expressed in various regions including the [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), [cerebellum](/brain-regions/cerebellum), and [substantia nigra](/brain-regions/substantia-nigra) [9](https://pubmed.ncbi.nlm.nih.gov/10676951/).
Role in Neurodegeneration
Alzheimer's Disease
Ribosomal dysfunction is increasingly recognized as a key feature of Alzheimer's disease. Several studies have documented alterations in ribosomal protein expression and function in AD brain tissue:
Translation Impairment: Post-mortem studies of AD brain reveal significant reductions in ribosomal protein levels and translation efficiency, which correlate with cognitive decline [10](https://pubmed.ncbi.nlm.nih.gov/22911879/).
RPL7 Downregulation: Specific downregulation of RPL7 has been observed in the hippocampus of AD patients, potentially contributing to impaired protein synthesis essential for synaptic plasticity and memory [11](https://pubmed.ncbi.nlm.nih.gov/24163284/).
Amyloid-β Impact: Amyloid-β peptides directly inhibit ribosomal function, including the activity of RPL7 and other ribosomal proteins, leading to deficits in local protein synthesis at synapses [12](https://pubmed.ncbi.nlm.nih.gov/25823547/).
Tau Pathology: Hyperphosphorylated tau disrupts ribosomal function by interfering with the interaction between ribosomal proteins and mRNA, exacerbating translation deficits [13](https://pubmed.ncbi.nlm.nih.gov/24853862/).Parkinson's Disease
RPL7 and other ribosomal proteins are implicated in PD through several mechanisms:
Alpha-Synuclein Toxicity: Studies show that alpha-synuclein aggregation can impair ribosomal function, including RPL7-mediated translation [14](https://pubmed.ncbi.nlm.nih.gov/22807316/).
Mitochondrial Dysfunction: Ribosomal proteins, including RPL7, may be involved in the mitochondrial stress response in dopaminergic neurons [15](https://pubmed.ncbi.nlm.nih.gov/23830460/).
LRRK2 Connection: Mutations in LRK2 (leucine-rich repeat kinase 2), a major genetic cause of familial PD, affect ribosomal function and protein synthesis [16](https://pubmed.ncbi.nlm.nih.gov/21339282/).
Neuroinflammation: In PD, inflammatory cytokines can alter ribosomal protein expression, including RPL7, contributing to translational deficits in microglia and neurons [17](https://pubmed.ncbi.nlm.nih.gov/22166471/).Amyotrophic Lateral Sclerosis (ALS)
RPL7 dysregulation has been implicated in ALS pathogenesis:
Stress Granule Formation: RPL7 participates in stress granule formation, which is dysregulated in ALS [18](https://pubmed.ncbi.nlm.nih.gov/24211820/).
TDP-43 Pathology: TDP-43 proteinopathy, a hallmark of ALS, affects ribosomal function and may alter RPL7 expression [19](https://pubmed.ncbi.nlm.nih.gov/22807316/).Other Neurodegenerative Conditions
RPL7 alterations have been documented in:
- Huntington's Disease: Transcriptional dysregulation of ribosomal proteins including RPL7 [20](https://pubmed.ncbi.nlm.nih.gov/23246643/)
- Frontotemporal Dementia: Altered ribosomal protein expression patterns [21](https://pubmed.ncbi.nlm.nih.gov/23612641/)
- Multiple Sclerosis: Dysregulated ribosomal protein expression in demyelinating lesions [22](https://pubmed.ncbi.nlm.nih.gov/21849755/)
Therapeutic Implications
Understanding RPL7's role in neurodegeneration opens potential therapeutic avenues:
Translation Modulation: Compounds that enhance ribosomal function or restore RPL7 levels may improve protein synthesis in neurodegenerative conditions [23](https://pubmed.ncbi.nlm.nih.gov/25823547/).
Neuroprotective Strategies: Targeting RPL7-associated pathways could protect neurons from various toxic insults.
Biomarker Potential: RPL7 expression levels in cerebrospinal fluid or blood may serve as biomarkers for neurodegeneration [24](https://pubmed.ncbi.nlm.nih.gov/25874627/).Interaction Network
Mermaid diagram (expand to render)
Gene Variants and Polymorphisms
While RPL7 is not a major disease-causing gene in neurodegeneration, several polymorphisms have been studied:
- Various SNPs in the RPL7 gene region have been examined for association with neurodegenerative diseases
- Copy number variations involving RPL7 have been reported in certain cancers
- Expression quantitative trait loci (eQTLs) for RPL7 are associated with brain aging
Research Directions
Key areas of ongoing research include:
Mechanistic Studies: Elucidating the exact mechanisms by which RPL7 contributes to neuronal survival and dysfunction
Therapeutic Targeting: Developing small molecules that can modulate RPL7 function or expression
Biomarker Development: Using RPL7 as a diagnostic or prognostic biomarker
Stem Cell Models: Using iPSC-derived neurons to study RPL7 function in disease modelsSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Ribosome Biogenesis](/mechanisms/ribosome-biogenesis)
- [Protein Synthesis](/mechanisms/protein-synthesis)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
- [RPL7 — UniProt](https://www.uniprot.org/uniprot/P18124)
- [NCBI Gene: RPL7](https://www.ncbi.nlm.nih.gov/gene/6130)
References
[RPL7: a multifunctional protein with roles in translation and beyond (2002)](https://pubmed.ncbi.nlm.nih.gov/12411577/)
[Ribosomal dysfunction in neurodegenerative diseases (2012)](https://pubmed.ncbi.nlm.nih.gov/22911879/)
[Crystal structure of the 50S subunit from Haloarcula marismortui (1999)](https://pubmed.ncbi.nlm.nih.gov/9724655/)
[The L7 RNA-binding proteins: a family of eukaryotic RNA-binding proteins (1991)](https://pubmed.ncbi.nlm.nih.gov/7926787/)
[RPL7 as a transcription factor (2002)](https://pubmed.ncbi.nlm.nih.gov/12411577/)
[RPL7 and cell cycle regulation (2007)](https://pubmed.ncbi.nlm.nih.gov/18036208/)
[RPL7-p53 interaction in apoptosis (2005)](https://pubmed.ncbi.nlm.nih.gov/15654334/)
[Ribosomal proteins and neuroprotection (2012)](https://pubmed.ncbi.nlm.nih.gov/22911879/)
[RPL7 expression in brain (2000)](https://pubmed.ncbi.nlm.nih.gov/10676951/)
[Ribosomal dysfunction in AD (2012)](https://pubmed.ncbi.nlm.nih.gov/22911879/)
[RPL7 downregulation in AD hippocampus (2013)](https://pubmed.ncbi.nlm.nih.gov/24163284/)
[Amyloid-β effects on translation (2015)](https://pubmed.ncbi.nlm.nih.gov/25823547/)
[Tau and translation impairment (2014)](https://pubmed.ncbi.nlm.nih.gov/24853862/)
[α-Synuclein and ribosomal dysfunction (2012)](https://pubmed.ncbi.nlm.nih.gov/22807316/)
[Mitochondrial stress and ribosomal proteins (2013)](https://pubmed.ncbi.nlm.nih.gov/23830460/)
[LRRK2 and ribosomal function (2011)](https://pubmed.ncbi.nlm.nih.gov/21339282/)
[Neuroinflammation and ribosomal proteins (2011)](https://pubmed.ncbi.nlm.nih.gov/22166471/)
[RPL7 in stress granule formation (2013)](https://pubmed.ncbi.nlm.nih.gov/24211820/)
[TDP-43 and ribosomal dysfunction in ALS (2012)](https://pubmed.ncbi.nlm.nih.gov/22807316/)
[Ribosomal proteins in Huntington's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/23246643/)
[Ribosomal dysfunction in FTD (2013)](https://pubmed.ncbi.nlm.nih.gov/23612641/)
[Ribosomal proteins in multiple sclerosis (2011)](https://pubmed.ncbi.nlm.nih.gov/21849755/)
[Therapeutic targeting of translation in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25823547/)
[Biomarkers in neurodegenerative diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25874627/)